Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 24, 20 December 2023
Open
Access | Article
The use of oncolytic virus to combat neuroblastoma
* Author to whom correspondence should be addressed.
Abstract
Neuroblastoma is a type of cancer that arises from immature nerve cells in the body and often appears in children. The current treatment of chemotherapy and radiotherapy is not a successful method of treatment due to its harm to the child’s body and its inability to effectively pass the blood-brain barrier (BBB) in the brain to effectively target the tumor. Recent studies into the field of oncolytic viruses have shown the possibility to target neuroblastoma cancer cells in the brain by engineering specific viruses to express NY-ESO-1, an antigen that is tumor-specific and commonly expressed in neuroblastoma. Research also showed a method to integrate protein A into the envelope protein of retroviruses which allows monoclonal antibodies’ Fc region to bind with the virus, allowing specificity to an antigen. This paper combines the ideas of previous studies to design a novel model of oncolytic virus treatment that specifically targets neuroblastoma. Since the oncolytic virus can be injected directly at the site and the virus is small enough to penetrate the BBB, the paper hypothesize that the model is a valid treatment for neuroblastoma in children.
Keywords
NY-ESO-1, HSV-1, Protein-A Integration, Monoclonal Antibodies, GM-CSF
References
1. Colon. (2011) Neuroblastoma. Advances in pediatrics. 58(1):297-311
2. Mohammad et al. (2008) A review of neuroblastoma: prevalence, diagnosis, related genetic factors, and treatment. Iran J Ped Hematol Oncol. Vol 8. No 4, 237-246
3. Sung KW. (2012) Treatment of high-risk neuroblastoma. Korean Journal of Pediatrics. 55(4):115-20.
4. Michael et al. (2018) Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci USA. 115(45): E10702-E10711
5. BL Liu et al. (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune-stimulating, and anti-tumor properties. Gene Ther. 10(4):292-303
6. KOUKI et al. (2001) Antibody-Directed Targeting of Retroviral Vectors via Cell. J Virol. 75(17):8016-20.
7. Johnson LA, et al. (2006) Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 177:6548–6559.
8. Hansford et al. (2004) Mechanisms of embryonal tumor initiation: distinct roles for MYCN expression and MYCN amplification. Proc Natl Acad Sci USA. 101: 12664– 12669.
9. Althoff et al. (2015) A Cre-conditional MYCN-driven neuroblastoma mouse. Oncogene. 34: 3357–3368
10. Chan et al. (1997) MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res. 3(10):1699-706.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-221-3
- ISBN (Online)
- 978-1-83558-222-0
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/24/20231094
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited